IGGA
AXSM icon

Iron Gate Global Advisors’s Axsome Therapeutics AXSM Stock Holding History

Iron Gate Global Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-250
Closed -$1K – 87
2018
Q3 		$1K Sell
250
-2,447
-91% -$7.25K ﹤0.01% 227
2018
Q2 		$9K Buy
+2,697
New +$8.36K 0.01% 146

Other funds holding AXSM

ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Iron Gate Global Advisors's AXSM Position: Q4 2018 in Review

Iron Gate Global Advisors sold out of Axsome Therapeutics (AXSM) in Q4 2018, closing a stake of 250 shares — an estimated $1K sold.

Iron Gate Global Advisors first reported a position in AXSM in Q2 2018 and held it in 2 quarters. The position peaked at $9K in Q2 2018. 35 funds tracked by Wall St. Rank hold AXSM as of Q4 2018.

  • Iron Gate Global Advisors reported no remaining Axsome Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Iron Gate Global Advisors sold 250 Axsome Therapeutics shares in Q4 2018, an estimated $1K.
  • Iron Gate Global Advisors first reported a position in Axsome Therapeutics in Q2 2018 and held it in 2 quarters.
  • Iron Gate Global Advisors's Axsome Therapeutics position peaked at $9K in Q2 2018.
  • 35 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2018.

Based on Iron Gate Global Advisors's 13F filing for Q4 2018, filed 19 Feb 2019.